Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05746559




Registration number
NCT05746559
Ethics application status
Date submitted
16/02/2023
Date registered
27/02/2023
Date last updated
27/06/2024

Titles & IDs
Public title
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
Scientific title
ARTEMIS: RAvulizumab to PRotect PaTients With Chronic Kidney DisEase (CKD) froM Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE): A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study
Secondary ID [1] 0 0
ALXN1210-CSA-AKI-318
Secondary ID [2] 0 0
D928DC00001
Universal Trial Number (UTN)
Trial acronym
ARTEMIS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Kidney Disease 0 0
CKD 0 0
Cardiac Disease 0 0
Cardiopulmonary Bypass 0 0
Condition category
Condition code
Renal and Urogenital 0 0 0 0
Kidney disease
Renal and Urogenital 0 0 0 0
Other renal and urogenital disorders
Cardiovascular 0 0 0 0
Coronary heart disease
Cardiovascular 0 0 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - Ravulizumab

Placebo comparator: Placebo - Participants will receive a single weight-based dose of placebo via intravenous infusion, 1 to 7 days prior to surgery.

Experimental: Ravulizumab - Participants will receive a single weight-based dose of ravulizumab, via intravenous infusion, 1 to 7 days prior to surgery.


Treatment: Drugs: Placebo
Participants will receive a single weight-based dose of placebo via intravenous infusion.

Treatment: Drugs: Ravulizumab
Participants will receive a single weight-based dose of ravulizumab via intravenous infusion.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants Experiencing Major Adverse Kidney Events (MAKE) (Based on serum Cystatin C [sCysC]) at Day 90 Post Cardiopulmonary Bypass (CPB)
Timepoint [1] 0 0
Day 90 post-CPB
Secondary outcome [1] 0 0
Number of Participants Free From Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) at Day 90 Post CPB
Timepoint [1] 0 0
Day 90 post-CPB
Secondary outcome [2] 0 0
Number of Participants Free From Severe CSA-AKI (Kidney Disease: Improving Global Outcomes [KDIGO] Stage 2 or 3) Based on Highest Observed Serum Creatinine (sCr) Within 7 Days Post CPB
Timepoint [2] 0 0
Baseline through Day 7 post-CPB
Secondary outcome [3] 0 0
Number of Participants Free From Any Severe Acute Kidney Injury (AKI) (Risk, Injury, Failure, Loss of Kidney Function, and End-Stage Kidney Disease [RIFLE] Injury or Failure Criteria) Based on Highest Observed sCr Within Day 30 Post CPB
Timepoint [3] 0 0
Baseline through Day 30 post-CPB
Secondary outcome [4] 0 0
Number of Participants Free From Any Severe AKI (KDIGO Stage 2 or 3) Based on Highest Observed sCr Within Day 30 Post CPB
Timepoint [4] 0 0
Baseline through Day 30 post-CPB
Secondary outcome [5] 0 0
Number of Participants Free From Any RIFLE Failure Criteria Based on Highest Observed sCr Within Day 30 Post CPB
Timepoint [5] 0 0
Baseline through Day 30 post-CPB
Secondary outcome [6] 0 0
Number of Participants Who Experienced MAKE at Days 30, 60, and 90 (Excluding MAKE90 Based on sCysC) Post CPB
Timepoint [6] 0 0
Days 30, 60, and 90 post-CPB
Secondary outcome [7] 0 0
Number of Participants Who Died or had Kidney Replacement Therapy (KRT) at Days 30, 60, and 90 Post CPB
Timepoint [7] 0 0
Days 30, 60, and 90 post-CPB
Secondary outcome [8] 0 0
Number of Participants with the Highest CSA-AKI Stage Within 3 and 7 Days Post CPB
Timepoint [8] 0 0
Baseline through Day 3 and Day 7 post-CPB
Secondary outcome [9] 0 0
Number of Participants Free From CSA-AKI at Days 15, 30, and 60 Post CPB
Timepoint [9] 0 0
Days 15, 30, and 60 post-CPB
Secondary outcome [10] 0 0
Number of Participants Free From Any AKI at Days 3, 7, 15, 30, 60, and 90 Post CPB
Timepoint [10] 0 0
Days 3, 7, 15, 30, 60, and 90 post-CPB
Secondary outcome [11] 0 0
Number of Participants with AKI Progression on Days 15, 30, 60, and 90 Post CPB for Those Experiencing CSA-AKI Within 7 Days Post CPB
Timepoint [11] 0 0
Days 15, 30, 60, and 90 post-CPB

Eligibility
Key inclusion criteria
* Participant weighs = 30 kg
* Planned non-emergent sternotomy with CPB procedure for the following surgeries:
* Multi-vessel CABG
* Valve replacement or repair; ascending aorta surgery permitted if combined with aortic valve replacement/repair
* Combined CABG and valve surgery; inclusion of single-vessel CABG when combined with valve replacement/repair is permitted
* Known CKD for at least 90 days (CKD Stage 3A, 3B, or 4)
Minimum age
18 Years
Maximum age
90 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Emergency or salvage cardiac surgery is expected at screening or randomization, as assessed by the Investigator.
* Single-vessel CABG without valve surgery is planned.
* Off-pump surgery is planned (eg, surgery without CPB).
* Recipient of a solid organ or bone marrow transplantation.
* Cardiogenic shock, hemodynamic instability, use of intra-aortic balloon pump, extracorporeal membrane oxygenation, or left ventricular assist device within 72 hours of randomization.
* Active systemic bacterial, viral, or fungal infection within 14 days prior to randomization.
* History of unexplained, recurrent infection.
* Any use of KRT or presence of AKI within 30 days of randomization
* Use of any complement inhibitors, or plasmapheresis or plasma exchange within the year prior to Screening, or planned use during the course of the study.
* Participant is not willing to be vaccinated against N meningitidis or is unwilling to receive prophylactic treatment with appropriate antibiotics, if needed
* History of or unresolved N meningitidis infection.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
6/04/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
17/05/2026
Actual
Sample size
Target
736
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Brisbane
Recruitment hospital [2] 0 0
Research Site - Canberra
Recruitment hospital [3] 0 0
Research Site - Heidelberg
Recruitment hospital [4] 0 0
Research Site - Monash
Recruitment hospital [5] 0 0
Research Site - Murdoch
Recruitment hospital [6] 0 0
Research Site - Southport
Recruitment postcode(s) [1] 0 0
4102 - Brisbane
Recruitment postcode(s) [2] 0 0
2605 - Canberra
Recruitment postcode(s) [3] 0 0
3081 - Heidelberg
Recruitment postcode(s) [4] 0 0
- Monash
Recruitment postcode(s) [5] 0 0
6150 - Murdoch
Recruitment postcode(s) [6] 0 0
4215 - Southport
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
Nebraska
Country [14] 0 0
United States of America
State/province [14] 0 0
New Jersey
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
North Dakota
Country [18] 0 0
United States of America
State/province [18] 0 0
Ohio
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
South Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Utah
Country [23] 0 0
United States of America
State/province [23] 0 0
Virginia
Country [24] 0 0
United States of America
State/province [24] 0 0
Washington
Country [25] 0 0
United States of America
State/province [25] 0 0
Wisconsin
Country [26] 0 0
Argentina
State/province [26] 0 0
Buenos Aires
Country [27] 0 0
Argentina
State/province [27] 0 0
Caba
Country [28] 0 0
Argentina
State/province [28] 0 0
Ciudad Autónoma de Bs. As.
Country [29] 0 0
Argentina
State/province [29] 0 0
Cordoba
Country [30] 0 0
Argentina
State/province [30] 0 0
Corrientes
Country [31] 0 0
Argentina
State/province [31] 0 0
Córdoba
Country [32] 0 0
Argentina
State/province [32] 0 0
San Luis
Country [33] 0 0
Argentina
State/province [33] 0 0
Santa Fé
Country [34] 0 0
Brazil
State/province [34] 0 0
Belo Horizonte
Country [35] 0 0
Brazil
State/province [35] 0 0
Campinas
Country [36] 0 0
Brazil
State/province [36] 0 0
Fortaleza
Country [37] 0 0
Brazil
State/province [37] 0 0
Porto Alegre
Country [38] 0 0
Brazil
State/province [38] 0 0
Ribeirão Preto
Country [39] 0 0
Brazil
State/province [39] 0 0
S.J. Do Rio Preto
Country [40] 0 0
Brazil
State/province [40] 0 0
Salvador
Country [41] 0 0
Brazil
State/province [41] 0 0
Sao Paulo
Country [42] 0 0
Brazil
State/province [42] 0 0
São Paulo
Country [43] 0 0
Canada
State/province [43] 0 0
Alberta
Country [44] 0 0
Canada
State/province [44] 0 0
New Brunswick
Country [45] 0 0
Canada
State/province [45] 0 0
Ontario
Country [46] 0 0
Canada
State/province [46] 0 0
Quebec
Country [47] 0 0
China
State/province [47] 0 0
Fuzhou
Country [48] 0 0
China
State/province [48] 0 0
Gaozhou
Country [49] 0 0
China
State/province [49] 0 0
Guangzhou
Country [50] 0 0
China
State/province [50] 0 0
Hangzhou
Country [51] 0 0
China
State/province [51] 0 0
Ningbo
Country [52] 0 0
China
State/province [52] 0 0
Shanghai
Country [53] 0 0
China
State/province [53] 0 0
Shenzhen
Country [54] 0 0
China
State/province [54] 0 0
Tianjin
Country [55] 0 0
China
State/province [55] 0 0
Wuhan
Country [56] 0 0
China
State/province [56] 0 0
Zhengzhou
Country [57] 0 0
Germany
State/province [57] 0 0
Dresden
Country [58] 0 0
Germany
State/province [58] 0 0
Essen
Country [59] 0 0
Germany
State/province [59] 0 0
Frankfurt am Main
Country [60] 0 0
Germany
State/province [60] 0 0
Giessen
Country [61] 0 0
Germany
State/province [61] 0 0
Halle (Saale)
Country [62] 0 0
Germany
State/province [62] 0 0
Heidelberg
Country [63] 0 0
Germany
State/province [63] 0 0
Jena
Country [64] 0 0
Germany
State/province [64] 0 0
Muenster
Country [65] 0 0
Germany
State/province [65] 0 0
München
Country [66] 0 0
Germany
State/province [66] 0 0
Stuttgart
Country [67] 0 0
Germany
State/province [67] 0 0
Trier
Country [68] 0 0
Hong Kong
State/province [68] 0 0
Hong Kong
Country [69] 0 0
India
State/province [69] 0 0
Bangalore
Country [70] 0 0
India
State/province [70] 0 0
Delhi
Country [71] 0 0
India
State/province [71] 0 0
Gurgaon
Country [72] 0 0
India
State/province [72] 0 0
Hyderabad
Country [73] 0 0
India
State/province [73] 0 0
Mysuru
Country [74] 0 0
India
State/province [74] 0 0
Secunderabad
Country [75] 0 0
Israel
State/province [75] 0 0
Haifa
Country [76] 0 0
Israel
State/province [76] 0 0
Petah Tikva
Country [77] 0 0
Israel
State/province [77] 0 0
Ramat Gan
Country [78] 0 0
Italy
State/province [78] 0 0
Bari
Country [79] 0 0
Italy
State/province [79] 0 0
Milano
Country [80] 0 0
Italy
State/province [80] 0 0
Milan
Country [81] 0 0
Italy
State/province [81] 0 0
Napoli
Country [82] 0 0
Japan
State/province [82] 0 0
Bunkyo-ku
Country [83] 0 0
Japan
State/province [83] 0 0
Chuo-ku
Country [84] 0 0
Japan
State/province [84] 0 0
Kamakura-shi
Country [85] 0 0
Japan
State/province [85] 0 0
Kawasaki-shi
Country [86] 0 0
Japan
State/province [86] 0 0
Minato-ku
Country [87] 0 0
Japan
State/province [87] 0 0
Okayama-shi
Country [88] 0 0
Japan
State/province [88] 0 0
Sagamihara-shi
Country [89] 0 0
Japan
State/province [89] 0 0
Suginami
Country [90] 0 0
Japan
State/province [90] 0 0
Urayasu
Country [91] 0 0
Korea, Republic of
State/province [91] 0 0
Anyang-si
Country [92] 0 0
Korea, Republic of
State/province [92] 0 0
Busan
Country [93] 0 0
Korea, Republic of
State/province [93] 0 0
Daegu
Country [94] 0 0
Korea, Republic of
State/province [94] 0 0
Seongnam-si
Country [95] 0 0
Korea, Republic of
State/province [95] 0 0
Seoul
Country [96] 0 0
Netherlands
State/province [96] 0 0
Groningen
Country [97] 0 0
Netherlands
State/province [97] 0 0
Maastricht
Country [98] 0 0
Netherlands
State/province [98] 0 0
Rotterdam
Country [99] 0 0
Poland
State/province [99] 0 0
Bielsko-Biala
Country [100] 0 0
Poland
State/province [100] 0 0
Chrzanów
Country [101] 0 0
Poland
State/province [101] 0 0
Grudziadz
Country [102] 0 0
Poland
State/province [102] 0 0
Katowice
Country [103] 0 0
Poland
State/province [103] 0 0
Kraków
Country [104] 0 0
Poland
State/province [104] 0 0
Poznan
Country [105] 0 0
Poland
State/province [105] 0 0
Szczecin
Country [106] 0 0
Poland
State/province [106] 0 0
Tychy
Country [107] 0 0
Poland
State/province [107] 0 0
Warszawa
Country [108] 0 0
Poland
State/province [108] 0 0
Lódz
Country [109] 0 0
Spain
State/province [109] 0 0
A Coruna
Country [110] 0 0
Spain
State/province [110] 0 0
Barcelona
Country [111] 0 0
Spain
State/province [111] 0 0
Córdoba
Country [112] 0 0
Spain
State/province [112] 0 0
Madrid
Country [113] 0 0
Spain
State/province [113] 0 0
Majadahonda
Country [114] 0 0
Spain
State/province [114] 0 0
Navarra
Country [115] 0 0
Spain
State/province [115] 0 0
Santander
Country [116] 0 0
Spain
State/province [116] 0 0
Sevilla
Country [117] 0 0
Spain
State/province [117] 0 0
Valencia
Country [118] 0 0
Spain
State/province [118] 0 0
Valladolid
Country [119] 0 0
Taiwan
State/province [119] 0 0
Hualien City
Country [120] 0 0
Taiwan
State/province [120] 0 0
New Taipei
Country [121] 0 0
Taiwan
State/province [121] 0 0
Taichung
Country [122] 0 0
Taiwan
State/province [122] 0 0
Tainan City
Country [123] 0 0
Taiwan
State/province [123] 0 0
Taipei City
Country [124] 0 0
Turkey
State/province [124] 0 0
Ankara
Country [125] 0 0
Turkey
State/province [125] 0 0
Istanbul
Country [126] 0 0
United Kingdom
State/province [126] 0 0
Cambridge
Country [127] 0 0
United Kingdom
State/province [127] 0 0
Clydebank
Country [128] 0 0
United Kingdom
State/province [128] 0 0
Edinburgh
Country [129] 0 0
United Kingdom
State/province [129] 0 0
London
Country [130] 0 0
United Kingdom
State/province [130] 0 0
Newcastle upon Tyne

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Alexion Pharmaceuticals, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.
Trial website
https://clinicaltrials.gov/study/NCT05746559
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Alexion Pharmaceuticals, Inc. (Sponsor)
Address 0 0
Country 0 0
Phone 0 0
1-855-752-2356
Fax 0 0
Email 0 0
clinicaltrials@alexion.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05746559